Toggle Bio — SEC Form D Filing
Toggle Bio filed an SEC Form D on October 6, 2026, reporting $200K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 6, 2026
- Amount reported
- $200K
- Round stage
- Pre-seed because a $200,000 raise via SAFEs is typical for early-stage proof-of-concept and initial IP filing in biotechnology.
- Industry
- Biotechnology
- Website
- https://toggle.bio
What the company does
Securities: SAFEs. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Traditional gene therapies and biologics lack precise, reversible control mechanisms, leading to off-target toxicity and limited therapeutic windows.
Solution
Toggle Bio develops programmable synthetic biology switches that allow researchers and clinicians to precisely toggle gene expression and therapeutic activity on and off.
Why now
Recent advancements in CRISPR, synthetic gene circuits, and precision medicine have created an urgent demand for dynamic control systems to make cell and gene therapies safer.
Source: SEC EDGAR Form D filing